mTORC1
- [1]. Zask A, et al. Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review. Expert Opin Ther Pat. 2011 Jul;21(7):1109-27. [Content Brief]
- [2]. Feldman ME, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009 Feb 10;7(2):e38. [Content Brief]
- [3]. Alqurashi N, et al. Chemical Inhibitors and microRNAs (miRNA) Targeting the Mammalian Target of Rapamycin (mTOR) Pathway: Potential for Novel Anticancer Therapeutics. Int J Mol Sci. 2013 Feb 13;14(2):3874-900. [Content Brief]
- [4]. Afzal O, et al. mTOR as a Potential Target for the Treatment of Microbial Infections, Inflammatory Bowel Diseases, and Colorectal Cancer. Int J Mol Sci. 2022 Oct 18;23(20):12470. [Content Brief]
- [5]. Liu Y, et al. The role of phospholipase D in modulating the MTOR signaling pathway in polycystic kidney disease. PLoS One. 2013 Aug 23;8(8):e73173. [Content Brief]
- [6]. Riaz H, et al. mTOR inhibitors: A novel class of anti-cancer agents. Infect Agent Cancer. 2012 Jan 3;7(1):1. [Content Brief]
- [7]. Zhou Y, et al. mTORC1 pathway is involved in the kappa opioid receptor activation-induced increase in excessive alcohol drinking. Pharmacol Biochem Behav. 2020;194:172954. [Content Brief]
- [8]. Ghosh A, et al. Investigation of the guaiazulene-p-chloranil charge transfer complex in solution: a combined spectroscopic and quantum chemical approach. Sci Rep. 2026 Jun 8. [Content Brief]
- [9]. Xiao H, et al. Amino acids regulate energy utilization through mammalian target of rapamycin complex 1 and adenosine monophosphate activated protein kinase pathway in porcine enterocytes. Anim Nutr. 2020 Mar;6(1):98-106. [Content Brief]
- [10]. Bond ME, et al. A central role for TOR signalling in a yeast model for juvenile CLN3 disease. Microb Cell. 2015 Nov 11;2(12):466-480. [Content Brief]
- [11]. Völkers M, et al. mTOR/PRAS40 interaction: hypertrophy or proliferation. Cell Cycle. 2013 Dec 1;12(23):3579-80. [Content Brief]
- [12]. Huan J, et al. Emerging Roles for Mammalian Target of Rapamycin (mTOR) Complexes in Bladder Cancer Progression and Therapy. Cancers (Basel). 2022 Mar 18;14(6):1555. [Content Brief]
- [13]. Subbiah V, et al. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer Res Commun. 2024 Feb 12;4(2):378-387. [Content Brief]
-
mTORC1 Related Products (82)
Related Products (82)
-
Antibodies (1)
-
PQR620
0 ImagesPQR620 is an orally bioavailable and selective brain penetrant inhibitor of mTORC1/2. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
- GDC-0349
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
2,8-Dihydroxyadenine
0 ImagesCat. No.: HY-N9941CAS No.: 30377-37-82,8-Dihydroxyadenine is an endogenous metabolite that forms crystals in urine, leading to kidney stone formation and crystal deposition in the kidney. 2,8-Dihydroxyadenine induces crystal-induced tubular injury, inflammation, and fibrosis through crystal deposition in renal tubules, where crystals are excreted in urine, internalized by tubular epithelial cells, and transported to the interstitium. 2,8-Dihydroxyadenine upregulates CD44 expression near crystals, TNF-α signaling through NF-κB, and mTORC1 signaling, while inducing actin stress fiber formation and cytoskeletal remodeling. 2,8-Dihydroxyadenine downregulates epithelial-mesenchymal transition pathways and oxidative phosphorylation, and induces changes affecting inflammation, metabolism, and cell cycle regulation. 2,8-Dihydroxyadenine can be used in research on kidney disease, adenine phosphoribosyltransferase deficiency, and kidney stone disease. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
MTI-31
0 ImagesSynonyms: LXI-15029MTI-31 (LXI-15029) is a potent, orally active and highly selective inhibitor of mTORC1 and mTORC2. MTI-31 is selective for mTOR (Kd: 0.20 nM) versus PIK3CA, PIK3CB and PIK3G with >5,000 fold selectivity in mTOR binding assays. MTI-31 shows an IC50 of 39 nM for mTOR in LANCE assay of mTOR substrate phosphorylation with 100 μM ATP. MTI-31 can be used for the research of breast cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Rapamycin (GMP)
0 ImagesCat. No.: HY-10219GCAS No.: 53123-88-9Synonyms: Sirolimus (GMP); AY-22989 (GMP); NSC 226080 (GMP)Rapamycin (Sirolimus) (GMP) is Rapamycin (HY-10219) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin (Sirolimus; AY 22989) is a potent and specific blood-brain barrier-transmissible mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin is a molecular glue that binds FKBP12 and mTOR proteins together, thereby inhibiting mTOR kinase activity. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
- XL388
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Endoxifen (Z-isomer hydrochloride)
0 ImagesEndoxifen Z-isomer hydrochloride is an orally active selective PKCβ1 inhibitor with an IC50 of 360 nM against human PKCβ1. It also acts as an estrogen receptor modulator and antiestrogen. Endoxifen Z-isomer hydrochloride binds to and blocks ERα, ERβ and PKCβ1, inhibits estrogen and PI3K/AKT/mTORC1 signaling pathways, suppresses the expression of genes associated with cell cycle, cell proliferation and extracellular matrix remodeling, and induces apoptosis, reactive oxygen species (ROS) production and hypoxic features. Endoxifen Z-isomer hydrochloride inhibits tumor growth in breast tumor and glioblastoma models, reduces bone turnover and blood lipid levels, and does not require metabolism via CYP2D6. It can be used in research related to ER+ breast cancer, invasive breast cancer, glioblastoma multiforme, type I bipolar disorder, desmoid tumor, gynecological malignancies, melanoma and hormone receptor-positive solid tumors. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
MT 63-78
0 ImagesMT 63-78 is a specific and potent direct AMPK activator with an EC50 of 25 μM. MT 63–78 also induces cell mitotic arrest and apoptosis. MT 63-78 blocks prostate cancer growth by inhibiting the lipogenesis and mTORC1 pathways. MT 63-78 has antitumor effects. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Rapamycin-d3
0 ImagesCat. No.: HY-10219SCAS No.: 392711-19-2Synonyms: Sirolimus-d3; AY-22989-d3; NSC 226080-d3Rapamycin-d3 (Sirolimus-d3; AY-22989-d3; NSC 226080-d3) is the deuterated-labeled Rapamycin (HY-10219). Rapamycin (Sirolimus; AY 22989) is a potent and specific blood-brain barrier-transmissible mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin is a molecular glue that binds FKBP12 and mTOR proteins together, thereby inhibiting mTOR kinase activity. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Rapamycin (GMP Like)
0 ImagesSynonyms: Sirolimus (GMP Like); AY-22989 (GMP Like); NSC 226080 (GMP Like)Rapamycin (Sirolimus) GMP Like is Rapamycin (HY-10219) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin (Sirolimus; AY 22989) is a potent and specific blood-brain barrier-transmissible mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin is a molecular glue that binds FKBP12 and mTOR proteins together, thereby inhibiting mTOR kinase activity. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
- FT-1518
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Sulindac sulfone
0 ImagesSulindac sulfone is an orally active metabolite of Sulindac (HY-B0008). Sulindac sulfone activates PPARγ and drives transcriptional induction of SSAT by binding to the PPRE-2 element. Sulindac sulfone induces Apoptosis. Sulindac sulfone negatively regulates the function of VDAC1/2 to inhibit the mTORC1 pathway, reduces Cyclin D1 levels, and induces G1 cell cycle arrest in colon cancer cells. Sulindac sulfone exerts colon cancer preventive effects through a COX-independent mechanism. Sulindac sulfone can be used in research related to colon cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
- WYE-687
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Rapamycin-13C,d3
0 ImagesCat. No.: HY-10219S1Synonyms: Sirolimus-13C,d3; AY-22989-13C,d3 NSC 226080-13C,d3Rapamycin-13C,d3 (Sirolimus-13C,d3) is the 13C, deuterated-labeled Rapamycin (HY-10219). Rapamycin (Sirolimus; AY 22989) is a potent and specific blood-brain barrier-transmissible mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin is a molecular glue that binds FKBP12 and mTOR proteins together, thereby inhibiting mTOR kinase activity. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Darlifarnib
0 ImagesCat. No.: HY-172423CAS No.: 3065226-39-0Synonyms: KO-2806Darlifarnib (KO-2806) is an orally active farnesyl transferase inhibitor. Darlifarnib inhibits the mTORC1 signaling pathway, thereby enhancing the anti-angiogenic properties of tyrosine kinase inhibitors. When used in combination with anti-VEGFR tyrosine kinase inhibitors, Darlifarnib promotes renal cell carcinoma tumor regression and inhibits tumor neovascularization. Darlifarnib sensitizes renal cell carcinoma tumors that progress after anti-VEGFR TKI treatment. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
- AZD3147
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
- WYE-687 dihydrochloride
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
CC214-2
0 ImagesCC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219)-resistant signaling and the growth of glioblastomas in vitro and in vivo. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Coronarin A
0 ImagesCoronarin A is an orally active natural compound that inhibits mTORC1 and S6K1 to increase IRS1 activity. Coronarin A shows anti-inflammatory activity and can also be used for type 2 diabetes mellitus research. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
FGF7p
0 ImagesFGF7p is a small molecule peptide and a potential bladder protector. FGF7p can activate downstream signaling pathways of FGFR2 in the urinary tract epithelium (pFRS2α, pAKT and pERK). FGF7p alleviates cyclophosphamide induced apoptosis and tissue damage in urinary tract epithelial cells by activating AKT and its downstream anti apoptotic targets (pBAD, pS6/mTORC1). FGF7p is commonly used in the study of inflammatory conditions. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
-
0 ImagesCat. No.:Synonyms:-
Host:
-
Application:
Human,
-
Isotype:
-
Reactivity:
,
-
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -